12-Week, Single-Center Study of a Targeted Pigment-Correcting Dark Spot Treatment for Post-Inflammatory Hyperpigmentation and Solar Lentigines

Abstract

Purpose Post-inflammatory hyperpigmentation (PIH) and solar lentigines are dark spots of skin from excessive melanin production due to injury or UV exposure. This 12-week single-center study assessed the efficacy and tolerability of a novel targeted pigment-correcting spot treatment gel suspension cream (Dark Spot Treatment) for improving mild-to-moderate PIH or solar lentigines. Patients and Methods Female participants (N = 41) aged 25–65 with mild-to-moderate facial dark spots applied Dark Spot Treatment daily for 12 weeks. Investigators assessed overall hyperpigmentation, skin tone evenness, and dark spot intensity, contrast, and size at Weeks 2, 4, 8, and 12. Participant self-assessments occurred at Weeks 1, 2, 4, 8, and 12. Tolerability was assessed by clinical grading and participant reporting. Results Dark Spot Treatment improved overall hyperpigmentation, skin tone evenness, and dark spot intensity and contrast at Weeks 2 through 12, and dark spot size at Weeks 4 through 12 (all p < 0.001 compared to baseline). Participant self-assessments showed high overall satisfaction. Dark Spot Treatment was well tolerated. Conclusion The novel pigment-correcting Dark Spot Treatment significantly improved the appearance of PIH and solar lentigines, had high participant satisfaction, and was well tolerated.

Efficacy and safety of novel topical pigment‐correcting regimen with biweekly diamond tip microdermabrasion procedures on facial hyperpigmentation

“…ABT was recently compared with 4% HQ as a stand‐alone treatment in individuals with moderate to severe facial hyperpigmentation, including melasma, across multiple races and ethnicities, including darker skin types, and was shown to be effective, well tolerated, and preferred over 4% HQ 22 . Spot Cream has previously been shown to provide significant improvement in dark spots from PIH/acne marks and age spots/solar lentigines by week 2 and through week 12 in a broad range of subject races, ethnicities, and skin types with high tolerability and patient satisfaction 23 …”

“…DG can be used in conjunction with Even & Correct Advanced Brightening Pro‐Infusion Serum (EC‐DG; SkinMedica, Allergan Aesthetics, an AbbVie Company), a novel, brightening pro‐infusion serum to improve the appearance of uneven or excess pigmentation. Even & Correct Advanced Brightening Treatment (ABT; SkinMedica, Allergan Aesthetics, an AbbVie Company) and Even & Correct Dark Spot Cream (Spot Cream; SkinMedica, Allergan Aesthetics, an AbbVie Company) are novel, hydroquinone (HQ)‐free, pigment‐correcting topical skincare products that target multiple cellular pathways in melanogenesis to treat broadly dispersed hyperpigmentation and dark spots (such as PIH and solar lentigines), respectively 22,23 …”

“…[19][20][21] DiamondGlow® (DG; Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA) is a noninvasive, in-office procedure using a pro- (HQ)-free, pigment-correcting topical skincare products that target multiple cellular pathways in melanogenesis to treat broadly dispersed hyperpigmentation and dark spots (such as PIH and solar lentigines), respectively. 22,23 The objective of this study was to assess cosmetic changes in subjects with mild to severe overall facial hyperpigmentation who received a combination of a series of 6 DG procedures using EC-DG, along with an at-home skincare regimen comprising ABT and spot cream. on a modified Griffiths 10-point scale).…”